PD -1/PD-L1 monoclonal antibody
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Soochow University, Shanghai Zhongshan Hospital, The First Affiliated Hospital with Nanjing Medical University, Tao Zhang
Conditions
Advanced Lung CancerChemotherapyImmune Checkpoint InhibitorImmunotherapyLymphopeniaNSCLC (Advanced Non-small Cell Lung Cancer)Post SurgicalPrimary Central Nervous System Lymphoma (PCNSL)
Early Phase 1
Phase 2
PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
RecruitingNCT07267234
Start: 2025-12-01End: 2027-09-01Target: 65Updated: 2026-10-27
Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC
Not yet recruitingNCT07353476
Start: 2026-06-01End: 2032-06-01Target: 38Updated: 2026-01-20
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
RecruitingNCT07410520
Start: 2026-02-07End: 2029-12-31Target: 50Updated: 2026-02-13
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
Not yet recruitingNCT07847229
Start: 2026-11-01End: 2028-04-30Target: 144Updated: 2026-10-06